|Budget Amount *help
¥1,600,000 (Direct Cost : ¥1,600,000)
Fiscal Year 1998 : ¥500,000 (Direct Cost : ¥500,000)
Fiscal Year 1997 : ¥1,100,000 (Direct Cost : ¥1,100,000)
1.Galanin shortened step-down latency of passive avoidance learning, while the dopamine DィイD21ィエD2 receptor agonist SKF38393, the dopamine DィイD22ィエD2 receptor agonist RU24213, the dopamine DィイD21ィエD2 receptor antagonist SCH23390 or the dopamine DィイD22ィエD2 receptor antagonist S(-)-sulpiride failed to influence it. Dynorphin A-(1-13) and SKF38393 markedly improved the galanin-induced shortening of step-down latency. However, RU24213, SCH23390 or S(-)-sulpiride did not affect the galanin-induced shortening of step-down latency.
The effects of intracerebroventricular administration of δィイD21ィエD2- and δィイD22ィエD2-selective opioid receptor agonists on spontaneous alternation performance, elevated plus-maze behavior and passive avoidance learning including step-down and step-through types were examined in mice. Although the δィイD21ィエD2-selective opioid receptor agonist, [D-PenィイD12ィエD1, L-PenィイD15ィエD1] enkephalin (DPLPE) or the δィイD22ィエD2-selective opioid receptor agonist, [D-AlaィイD12ィエD1] delto
rphin II (deltorphin) did not markedly affect spontaneous alternation performance or elevated plus-maze behavior, DPLPE and deltorphin inhibited passive avoidance learning including step-down and step-through types. The δィイD21ィエD2-selective opioid receptor antagonist, 7-benzylidenenaltrexone, and the δィイD22ィエD2-selective opioid receptor antagonist, naltriben, significantly antagonized the inhibitory effects of DPLPE and deltorphin on passive avoidance learning, respectively. In contrast, DPLPE or deltorphin did not markedly influence behavioral responses induced by electroshocks during training of passive avoidance learning.
3.The present study was designed to clarify whether opioid neuronal systems are involved in the beneficial effects of tachykinins such as the neurokinin NKィイD21ィエD2 receptor agonist, substance P(SP), the neurokinin NKィイD22ィエD2 receptor agonist, neurokinin A(NKA), and the neurokinin NKィイD23ィエD2 receptor agonist, senktide, on the scopolamine-induced impairment of spontaneous alternation performance in mice. Intracerebroventricular injections of SP, NKA and senktide inhibited the scopolamine-induced impairment of spontaneous alternation performance without influencing total arm entries, indicating the antiamnesic effects of tachykinins. Furthermore, the inhibitory effects of SP, but not those of NKA or senktide, were almost completely reversed by pretreatment with naloxone. However, the effects of SP on the scopolamine-induced impairment of spontaneous alternation performance were not influenced by pretreatment with the μ-opioid receptor antagonist, β-funaltrexamine, the δ-opioid receptor antagonist, naltrindole, and the κ-opioid receptor antagonist, nor-binaltorphimine. Less